13F reference period
Q2 2026
Security Snapshot
Oruka Therapeutics, Inc. - Common Stock, par value $0.001 per share (ORKA) Institutional Ownership
CUSIP: 687604108
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
255
Shares (Excl. Options)
74.14M
Full value: 74,139,131 · shares · 30 Jun 2026Price
$95.17
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ORKA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 74,139,131
- Total 13F value
- $7,051,100,780
- Portfolio coverage rank
- 0.01%
- Share change
- +19,675,810
- Value change
- +$1,979,836,886
- Number of holders
- 255
- Shares outstanding
- 61,580,432
- SEC-reported price per share
- $83.29
- Insider filing price
- $83.29
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ORKA - Oruka Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 687604108.
- 255 institutions reported positions in Q2 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 183 to 255 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$2.55B
Full value: $2,550,553,925 · USD · 31 Mar 2026.$7.05B
Full value: $7,051,100,780 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 255 institutions filings for Q2 2026.
Security key
687604108
13F reference period
Q2 2026
13F holders
255
13D/G owners
7
CIK / CUSIP context first
Open Q2 2026 holders
ORKA full holder history
Oruka Therapeutics, Inc. SEC filings
Oruka Therapeutics, Inc. company facts
Oruka Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 687604108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
ORKA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | -2.4% | $997,807,627 | +$62,159,599 | 14,572,917 | +6.6% | Harwin Peter Evan | 01 Jul 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 7.4% | -25% | $384,606,749 | -$29,765,095 | 4,556,952 | -7.2% | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2026 |
| Capital World Investors | 5.6% | $287,098,332 | 3,401,639 | Capital World Investors | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.6% | +42% | $96,248,890 | +$29,642,149 | 3,175,483 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 5.2% | +22% | $264,934,132 | +$91,226,441 | 3,139,030 | +53% | RTW Investments, LP | 30 Jun 2026 |
| Deep Track Capital, LP | 4.5% | -12% | $65,515,368 | +$8,023,966 | 2,161,510 | +14% | Deep Track Capital, LP | 31 Dec 2025 |
| VIKING GLOBAL INVESTORS LP | 2.5% | -56% | $126,893,543 | -$98,175,093 | 1,503,478 | -44% | VIKING GLOBAL INVESTORS LP | 30 Jun 2026 |
As of 30 Jun 2026,
255
institutional investors reported holding
shares of
Oruka Therapeutics, Inc. - Common Stock, par value $0.001 per share (ORKA).
This represents
120%
of the company’s total
outstanding shares.
74.14M
Full value: 74,139,131 · shares · 30 Jun 202661.58M
Full value: 61,580,432 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
92%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 9,057,645 | +22% | 0.04% | $862,016,075 |
| BlackRock, Inc. | 8.1% | 4,990,181 | +41% | 0.01% | $474,915,526 |
| Venrock Adviser, LLC | 6.7% | 4,148,428 | 0% | 12% | $394,805,893 |
| Fairmount Funds Management LLC | 6% | 3,705,262 | 0% | 23% | $352,629,785 |
| Capital World Investors | 5.5% | 3,401,639 | 0.04% | $323,733,984 | |
| RTW INVESTMENTS, LP | 5.1% | 3,139,030 | +53% | 2.6% | $298,741,485 |
| STATE STREET CORP | 4.3% | 2,673,090 | +66% | 0.01% | $254,384,117 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.8% | 2,360,971 | +27% | 0% | $224,693,610 |
| Paradigm Biocapital Advisors LP | 3.5% | 2,144,526 | -7.6% | 3.8% | $204,094,539 |
| Deep Track Capital, LP | 3.1% | 1,926,000 | -5.3% | 2.7% | $183,297,420 |
| Bellevue Group AG | 2.7% | 1,657,190 | +227% | 3.3% | $157,714,772 |
| FRANKLIN RESOURCES INC | 2.6% | 1,621,451 | +61% | 0.03% | $154,313,446 |
| Remedium Capital Partners, LLC | 2.5% | 1,565,661 | 0% | 33% | $149,003,957 |
| RA CAPITAL MANAGEMENT, L.P. | 2.5% | 1,554,597 | 1.3% | $147,950,996 | |
| VIKING GLOBAL INVESTORS LP | 2.4% | 1,503,478 | -44% | 0.41% | $143,086,001 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.3% | 1,429,954 | +50% | 0.01% | $136,113,846 |
| Jupiter Topco LLC | 2.2% | 1,375,844 | 0% | 0.05% | $130,968,336 |
| PERCEPTIVE ADVISORS LLC | 2.2% | 1,345,063 | -3.6% | 2% | $128,009,646 |
| Polar Capital Holdings Plc | 2% | 1,228,609 | +17% | 0.33% | $116,926,719 |
| CITADEL ADVISORS LLC | 1.8% | 1,119,011 | +11% | 0.06% | $106,496,277 |
| T. Rowe Price Investment Management, Inc. | 1.8% | 1,103,743 | 0.07% | $105,044,000 | |
| BNP PARIBAS FINANCIAL MARKETS | 1.8% | 1,079,015 | 0% | 0.05% | $102,689,858 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.4% | 838,603 | +15% | 0.01% | $79,811,000 |
| Avidity Partners Management LP | 1.2% | 760,424 | 0% | 12% | $72,369,552 |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1.1% | 658,301 | 1.6% | $62,650,506 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 250,002 | $20,808,780 | -$3,010,096 | $83.29 | 33 |
| 2026 Q2 | 74,139,131 | $7,051,100,780 | +$1,979,836,886 | $95.17 | 255 |
| 2026 Q1 | 52,018,172 | $2,550,553,925 | +$46,411,060 | $49.05 | 183 |
| 2025 Q4 | 52,853,967 | $1,602,044,506 | +$170,793,609 | $30.31 | 144 |
| 2025 Q3 | 45,557,412 | $875,823,009 | +$220,884,566 | $19.23 | 104 |
| 2025 Q2 | 34,429,035 | $385,950,468 | +$30,431,109 | $11.21 | 81 |
| 2025 Q1 | 31,776,517 | $326,087,518 | -$21,453,560 | $10.26 | 70 |
| 2024 Q4 | 31,038,311 | $606,624,310 | +$125,781,752 | $19.39 | 66 |
| 2024 Q3 | 24,559,501 | $604,174,991 | +$603,646,384 | $24.51 | 41 |